Trend-Following Backtester · Guide · backtest 한국어

equity · IN

Zydus Lifesciences Limited backtest

10 trend-following strategies were compared on the full daily history of Zydus Lifesciences Limited. 2 beat buy-and-hold CAGR; SMA 크로스오버 ranks first by Sharpe, matching the main backtester. The return/drawdown alternative is ROC 모멘텀 (CAGR 17.7%, MDD -46.3%).

Data 2000-04-27 ~ 2026-07-31daily bars 6,551 (26.3 years)Costs 0.5%Venue NSEMonthly snapshot 2026-07-31

Results by strategy

2 of 10 beat buy and hold (CAGR 17.5%, drawdown -69.8%).

Sharpe leader (same as main): SMA 크로스오버 — CAGR 19.2%, MDD -48.0%, Sharpe 0.82, 60% exposure.

Return/drawdown alternative: ROC 모멘텀 — CAGR is 1.7%p higher than buy and hold, while drawdown improves by 21.8%p (CAGR 17.7%, MDD -46.3%, exposure 59%).

The alternative must retain 75% of buy-and-hold CAGR, improve drawdown by at least 20% and 5 percentage points, and stay below 95% exposure; the ranking weights return retention 60% and drawdown improvement 40%.

Strategy · parametersCAGRMDDSharpeCalmarTotalTradesExposure
SMA 크로스오버
fast=41, slow=160
19.2%-48.0%0.820.40101.0x3560%
ROC 모멘텀
n=105, threshold=0.01
17.7%-46.3%0.780.3873.0x17359%
EMA 크로스오버
fast=30, slow=68
16.5%-73.1%0.720.2355.0x5759%
볼린저 밴드 돌파
n=64, k=3
11.6%-33.3%0.700.3517.6x5330%
Supertrend
period=5, mult=5
15.9%-77.9%0.690.2048.6x5562%
Donchian 채널 돌파
entryN=118, exitN=35
13.2%-65.0%0.670.2025.9x3946%
Keltner 채널 돌파
emaPeriod=56, atrPeriod=8, mult=1.5
12.6%-59.6%0.630.2122.6x12145%
ADX / DI 방향성
period=37, threshold=17
10.1%-55.0%0.620.1812.6x11132%
MACD
fast=14, slow=48, signal=18
1.4%-77.7%0.190.021.5x31450%
Parabolic SAR
step=0.02, maxStep=0.24
0.9%-67.6%0.160.011.3x55052%
Buy and hold17.5%-69.8%0.650.2569.7x1100%
1x 10x 100x 2001 2005 2009 2013 2017 2021 2025 SMA 크로스오버Buy and hold
SMA 크로스오버: Solid strategy line versus dashed buy-and-hold line. Log scale.
0% -17% -35% -52% -70% 2001 2005 2009 2013 2017 2021 2025 Buy and holdSMA 크로스오버
SMA 크로스오버 maximum drawdown -48.0% (2006-05-02 → 2008-10-29), recovered after 1,267 days.

Rules of the top strategy

When the short average rises above the long average, it reads that as an uptrend starting.

Method and caveats

Past performance does not guarantee future returns. Parameters were selected on the same full-history sample using sharpe over 40 trials per strategy, so results contain in-sample bias. 0.5% trading costs are included; taxes, slippage and rejected orders are not.
Re-run the same setupAll asset reports

Read next